Clinical trial
Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular…
NCT00413790 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00413790 |
|---|---|
| Title | Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects |
| Official title | A 3-Way Cross-Over, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Pharmacologic Effects of a 7-Day Exposure to Darifenacin 15 mg o.d. and Tolterodine ER 4 mg o.d on Cardiovascular Parameters in Healthy Subjects 50 Years of Age and Older |
| Lead sponsor | Novartis, Industry |
| Collaborators | Procter and Gamble Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | Darifenacin, Tolterodine, Placebo |
| Enrollment | 162 |
| Start date | Nov 1, 2006 |
| Completion | Sep 1, 2007 |
| First posted | Dec 20, 2006 |
| Last update posted | Jan 15, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: